What is the secretion and mechanism of action of "growth hormone"?

Growth hormone, also known as somatotropin, is a peptide hormone secreted by the somatotroph cells of the anterior pituitary gland. Its secretion is primarily regulated by two hypothalamic hormones: growth hormone-releasing hormone (GHRH), which stimulates its synthesis and release, and somatostatin, which inhibits it. This secretion is pulsatile, with the most significant pulses occurring during deep sleep, underscoring the critical link between sleep physiology and growth processes. Additional factors influencing its release include nutritional status, stress, exercise, and other hormones like ghrelin, which acts as a potent secretagogue. The complex interplay of these regulatory signals ensures that growth hormone output is finely tuned to the body's metabolic and developmental needs, rather than being constitutively active.

The mechanism of action of growth hormone is characterized by a dual pathway system, involving both direct and indirect effects. Growth hormone exerts direct actions by binding to its specific transmembrane receptor, the growth hormone receptor, on target cells. This binding triggers a cascade of intracellular signaling, predominantly through the JAK-STAT pathway, leading to changes in gene expression that promote processes like lipolysis, glycogenolysis, and protein synthesis. However, a significant portion of its classic anabolic and growth-promoting effects are mediated indirectly through the stimulation of insulin-like growth factor-1 (IGF-1) production, primarily in the liver. IGF-1 then acts in an endocrine and paracrine fashion to stimulate cellular proliferation, particularly in cartilage and bone, which is essential for longitudinal growth.

The physiological implications of this mechanism are profound and extend well beyond childhood growth. In the developing organism, the growth hormone-IGF-1 axis is indispensable for normal skeletal and muscular development. In adults, where linear growth has ceased, growth hormone maintains crucial metabolic functions. It promotes a shift in substrate utilization, increasing the breakdown of stored fats for energy while conserving lean body mass and promoting protein synthesis. This catabolic effect on adipose tissue and anabolic effect on muscle creates a distinct metabolic profile. Consequently, dysregulation of this system has significant clinical consequences; deficiency in childhood leads to growth failure, while in adults it can contribute to altered body composition, reduced bone density, and impaired quality of life. Conversely, excess secretion, as seen in acromegaly, results in pathological tissue overgrowth and severe metabolic disturbances like insulin resistance.

Understanding this hormone's action also clarifies the rationale behind its therapeutic and illicit use. In clinical medicine, recombinant human growth hormone is a standard treatment for pediatric growth hormone deficiency and certain other conditions. Its anabolic and purported anti-aging properties have, however, led to its misuse in athletics and wellness contexts, despite significant risks such as glucose intolerance, fluid retention, and potential contribution to neoplasia. The precise, receptor-mediated signaling and the central role of IGF-1 as a mediator explain both its potent effects on body composition and the narrow therapeutic window that exists between its physiological benefits and pathological side effects.